Jos-Alain Sahel was on a rare vacation in Portugal in the spring of 2018 when his phone rang with grim news: The gene therapy he had worked on for a decade, a potential cure for a rare form of blindness, had failed in a pivotal trial.<\/p>\n
In the first minute, I was very disappointed, Sahel says. I said, well OK, its not working.<\/p>\n
A failed trial in drug development is crushing but not unexpected, a tradeoff of doing business in biology. You examine the full data, go back to the drawing board and either abandon the effort or tweak and try again. Sahel, founder of four companies and the longtime head of the Vision Institute of Paris, was used to the process. But this time, when the full data came, he was bewildered.<\/p>\n
Unlock this story instantly and join 95,700+ biopharma pros reading Endpoints daily and it's free. <\/p>\n
SUBSCRIBE SIGN IN <\/p>\n
<\/p>\n
Read the rest here:<\/p>\n
They thought their gene therapy failed. Instead, it spawned a medical mystery - Endpoints News<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Jos-Alain Sahel was on a rare vacation in Portugal in the spring of 2018 when his phone rang with grim news: The gene therapy he had worked on for a decade, a potential cure for a rare form of blindness, had failed in a pivotal trial. In the first minute, I was very disappointed, Sahel says Continue reading